HONG KONG, Sept. 11, 2026 /PRNewswire/ -- Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026) officially opened on September 9, 2026, at the Hong Kong Convention and Exhibition Centre. Marking a key 5-year milestone, this flagship life sciences event connects Hong Kong, Mainland China, and global markets, drawing industry leaders from around the world.
Centering on the core concept of "A Global Biotech Kaleidoscope," the 4-day convention features 7 main stages and over 50 multi-track parallel forums. It has attracted over 10,000 professional attendees from more than 40 countries and regions, over 500 world-class speakers, and nearly 200 premier domestic and international exhibitors. Positioned as a "Super Connector," BIOHK2026 bridges the complete chain of scientific breakthroughs, regulatory mutual recognition, capital enablement, industrialization, and global market access, unlocking Hong Kong's institutional, financial, and geographical advantages as an international biotech hub.
The grand opening ceremony brought together global dignitaries, Hong Kong SAR officials, Greater Bay Area (GBA) representatives, and event organizers to discuss public health, Hong Kong's innovation ecosystem, and regional integration. Mr. John KC Lee, Chief Executive of the Hong Kong SAR, sent a congratulatory message themed "A Convergence of Global Minds in Biotechnology, Advancing on the Road to Life Science Excellence and Future Prosperity," calling for collective action to shape the industry's future. Mr. Ban Ki-moon, 8th Secretary-General of the United Nations, also sent his congratulations, commending Hong Kong's role as a "Super Connector" and calling for deeper international collaboration to accelerate innovation delivery.
In his opening address, Prof. Albert Yu, President of BIOHK2026, reviewed the event's 5-year evolution into a global nexus for life sciences innovation, emphasizing its role in driving ideas toward market deployment. Mr. Leung Chun-ying, Vice Chairman of the National Committee of the CPPCC, highlighted opportunities under China's 15th Five-Year Plan and the Nansha Guangdong-Hong Kong cooperation framework.
Key government leaders, including Prof. Sun Dong, Secretary for Hong Kong Innovation, Technology and Industry, and Prof. Lo Chung-mau, Secretary for Hong Kong Health Bureau, shared insights on policy support and cross-border regulatory harmonization. Meanwhile, Mr. Chen Xu, Executive Deputy Director of the Guangzhou GBA Office, and Mr. Liu Chuwen, Member of the Party Leadership Group of the Shenzhen Municipal Development and Reform Commission, presented their cities' biotech foundations and cross-regional integration ideas based on Greater Bay Area integration.
Marking a major partnership milestone at the ceremony, CITIC Group, the Exclusive Strategic Partner of BIOHK2026, unveiled the CITIC Healthcare Industry Think Tank and signed a strategic cooperation framework agreement with the Hong Kong Biotechnology Organization (HKBIO). The agreement aims to build a cross-border industry-finance platform that accelerates the deployment of global biotech ventures. Additionally, the opening ceremony presented annual industry honors to celebrate pioneering individuals, outstanding enterprises, and key partners for their achievements in technical breakthroughs, commercialization, and cross-border collaboration.
Standing at the 5-year time node, BIOHK2026 embraces dual development opportunities: Hong Kong is planning its next five-year growth blueprint, while China enters a brand-new phase under the 15th 5-Year Plan. Life sciences represent both a national strategic emerging industry and a key technology track prioritized by Hong Kong; the development of BIOHK resonates synchronously with Hong Kong's urban positioning and the national demand for biotech innovation.
Over the coming days, collisions of ideas, project negotiations, and showcase achievements will continue to take place at the Exhibition Centre. BIOHK2026 has long evolved beyond the scope of a mere industry event—it serves not only as a hub for technical and intellectual exchange, but also as a venue for international regulatory dialogue and a launchpad for cross-border innovation transactions.
September 9-12, 2026 | BIOHK2026—Where Leaders Unite Biotech Advances
We cordially invite global biopharma executives, researchers, investors, regulators, clinical experts, and industry leaders to gather in Hong Kong and explore the new frontiers of biotechnology.
For further details, please contact us via the channels above.
About HKBIO
The Hong Kong Biotechnology Organization (HKBIO) is a leading non-profit organization dedicated to advancing the growth, internationalization, and innovation of Hong Kong's life sciences ecosystem. Bringing together leaders from government, industry, academia, research, and capital markets, HKBIO serves as a Super-Connector, fostering cross-border collaboration, accelerating clinical translation, and supporting the commercialization of biotechnology innovation across the Asia-Pacific region. Through its initiatives, HKBIO continues to strengthen Hong Kong's position as a leading international biotechnology and healthcare innovation hub while helping transform scientific breakthroughs into real-world healthcare solutions.
For more information, please visit https://www.bio-hk.com/.
SOURCE Hong Kong Biotechnology Organization
Share this article